RESEARCH TRIANGLE PARK, N.C.–(BUSINESS WIRE)–Tryton Medical, Inc. announced today that it has appointed J. Greg Davis
as President and Chief Executive Officer. Founded in 2003, Tryton
Medical is the leading developer of stents that are designed to
definitively treat bifurcation lesions.
Mr. Davis joins Tryton Medical after a successful 20-year career with
Guidant and Eli Lilly & Company. Mr. Davis is an experienced medical
device executive with broad global and functional experience in finance,
manufacturing, sales and general management. Most recently he was
president of Guidant, Japan with profit and loss responsibility for the
company’s $225 million cardiovascular business. Prior to his work in
Japan, Mr. Davis managed Guidant’s product portfolio in 13 Asian
countries. Mr. Davis earned a BS in Mechanical Engineering from The
University of Minnesota and an MBA from The University of Michigan.
“I am excited about this opportunity because I believe the Tryton
Side-Branch Stent™ will redefine the standard of care for bifurcation
lesions,” said Mr. Davis. “Tryton’s elegant design, ease-of-use and
stellar clinical results are impressive. I look forward to implementing
the company’s aggressive European commercialization strategy and U.S.
clinical trial plans.”
“We are delighted to welcome Greg to Tryton Medical during this pivotal
time in the company’s development,” said Dan Cole, Co-Founder and Board
Member of Tryton and General Partner of Spray Venture Partners. “We
believe his proven track record of growing successful businesses and
achieving results will enable Tryton to capitalize on its leadership
position in the industry.”
“Greg’s rich international experience and customer focus will be real
assets as we launch the Side-Branch Stent™ across Europe,” said Rick
Anderson, Board Member of Tryton and Managing Director of PTV Sciences,
and former Company Group Chairman, Cordis Corporation. “The Tryton 1
(First in Man) trial results and recent CE Mark approval have created
strong interest and enthusiasm among the European physician community.”
About Tryton Medical, Inc.
Tryton Medical, Inc. was founded in 2003 by Aaron V. Kaplan, M.D.
(Associate Professor of Medicine at Dartmouth Medical
School/Dartmouth-Hitchcock Medical Center) and Dan Cole to develop
stents for the definitive treatment of bifurcation lesions. The company
recently completed a $14 million round of financing, led by PTV Sciences
and RiverVest Venture Partners. The Company will be headquartered in
Research Triangle Park, NC. For more information on Tryton Medical
contact J. Greg Davis, at gdavis@trytonmedical.com
or visit trytonmedical.com.